characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2023-10-20T15:00:04Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2023-10-20T15:00:04Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA113936482
characteristics.characteristic: External Id
characteristics.text: LabMedMolGe
characteristics.characteristic: INSDC center name
characteristics.text: 2023-10-20T15:00:04Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-10-20T15:00:04Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS15930643
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-13103:Sample 1
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: DLD1
characteristics.characteristic: cell_line
characteristics.text: epithelial cell
characteristics.characteristic: cell_type
characteristics.text: not collected
characteristics.characteristic: collection date
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: Human colorectal adenocarcinoma cell lines DLD-1, were provided and grown as previously described [Proto et al., 2017; Notarnicola et al., 2008]. When indicated 48 hours before stimulation, growing cells at 70% confluence were made quiescent using phenol red-free RPMI medium containing 0.1% charcoal-stripped serum (CSS), penicillin (100 U/ml) and streptomycin (100 U/ml). The hEGF (Sigma Aldrich, St. Louis, Missouri, USA) was used at 100 ng/ml. The EGFR tyrosine kinase inhibitor, ZD1839, (Selleckem, Planegg, Germany) was used at 2 �M. The EGF neutralizing antibody (10605-R001; Sino Biological, Beijing, China) was used at 1,5 �g/ml. DLD-1-pEGFP and DLD-1-pEGFP_hRIZ2 cells were counted by the method of optical microscopy in the B�rker chamber. DLD-1-pEGFP_hRIZ2 cells were compared with DLD-1-pEGFP cells. total RNAs concentration was measured using RNA HS kit on a Qubit fuorimeter (Life Technologies, Monza, Italy) while its quality and integrity assessed with the Agilent 4200 Tapestation System (Agilent Technologies, Milan, Italy). For RNA sequencing experiments, indexed libraries were prepared using 500 ng of total RNA as starting material using the Illumina Stranded Total RNA prep Ligation with Ribo-Zero Plus kit (Illumina Inc., San Diego, CA, USA).
characteristics.characteristic: description
characteristics.text: colon adenocarcinoma
characteristics.characteristic: disease
characteristics.text: control
characteristics.characteristic: genetic modification
characteristics.text: not collected
characteristics.characteristic: geographic location (country and/or sea)
characteristics.text: not applicable
characteristics.characteristic: isolate
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: colon
characteristics.characteristic: organism part
characteristics.text: GFP_rep1
characteristics.characteristic: replicate
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: Sample 1
characteristics.characteristic: title